Christopher LaGanke

1.2k total citations
28 papers, 287 citations indexed

About

Christopher LaGanke is a scholar working on Pathology and Forensic Medicine, Oncology and Epidemiology. According to data from OpenAlex, Christopher LaGanke has authored 28 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Christopher LaGanke's work include Multiple Sclerosis Research Studies (17 papers), Polyomavirus and related diseases (8 papers) and Mycobacterium research and diagnosis (5 papers). Christopher LaGanke is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Polyomavirus and related diseases (8 papers) and Mycobacterium research and diagnosis (5 papers). Christopher LaGanke collaborates with scholars based in United States, Canada and Italy. Christopher LaGanke's co-authors include Tjalf Ziemssen, Ann Bass, Bart Van Wijmeersch, Anthony Traboulsee, Keith R. Edwards, B. Singer, Sharon Lynch, Robert T. Naismith, John E. Leonard and Lily Jung Henson and has published in prestigious journals such as Neurology, Annals of Neurology and Multiple Sclerosis Journal.

In The Last Decade

Christopher LaGanke

27 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher LaGanke United States 9 193 80 72 66 65 28 287
Yusuke Terada Japan 7 277 1.4× 241 3.0× 47 0.7× 71 1.1× 73 1.1× 16 417
Raffaele Murru Italy 11 183 0.9× 29 0.4× 61 0.8× 125 1.9× 77 1.2× 23 368
D. Teitelbaum Israel 9 138 0.7× 69 0.9× 50 0.7× 170 2.6× 67 1.0× 15 323
S. Galgani Italy 12 226 1.2× 120 1.5× 88 1.2× 213 3.2× 97 1.5× 15 533
René M. Gieß Germany 11 224 1.2× 73 0.9× 71 1.0× 74 1.1× 69 1.1× 16 333
Ciro Florio Italy 8 142 0.7× 44 0.6× 43 0.6× 107 1.6× 34 0.5× 12 270
Magdalena Lindén Sweden 10 152 0.8× 25 0.3× 59 0.8× 173 2.6× 56 0.9× 11 352
Maria Roberta Bongioanni Italy 8 190 1.0× 93 1.2× 95 1.3× 61 0.9× 97 1.5× 11 280
Ayal Rozenberg Israel 8 78 0.4× 31 0.4× 39 0.5× 89 1.3× 18 0.3× 16 226
Laura Boos Switzerland 9 42 0.2× 50 0.6× 67 0.9× 107 1.6× 14 0.2× 15 272

Countries citing papers authored by Christopher LaGanke

Since Specialization
Citations

This map shows the geographic impact of Christopher LaGanke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher LaGanke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher LaGanke more than expected).

Fields of papers citing papers by Christopher LaGanke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher LaGanke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher LaGanke. The network helps show where Christopher LaGanke may publish in the future.

Co-authorship network of co-authors of Christopher LaGanke

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher LaGanke. A scholar is included among the top collaborators of Christopher LaGanke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher LaGanke. Christopher LaGanke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Traboulsee, Anthony, Christopher LaGanke, Xavier Montalbán, et al.. (2020). Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis (804). Neurology. 94(15_supplement). 3 indexed citations
3.
Carruthers, Robert, Anthony Traboulsee, Ann Bass, et al.. (2019). Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology. 10. 253–253. 14 indexed citations
4.
Cuker, Adam, Ann Bass, Čongor Nadj, et al.. (2019). Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Multiple Sclerosis Journal. 26(1). 48–56. 34 indexed citations
5.
Chinea, Ángel, William Honeycutt, Tamara Miller, et al.. (2019). Effect of Alemtuzumab Infusions on Vital Signs. International Journal of MS Care. 22(2). 53–59. 6 indexed citations
6.
McDaniel, H. Reginald, et al.. (2018). The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis. Journal of Dietary Supplements. 17(2). 184–199. 9 indexed citations
7.
8.
9.
10.
LaGanke, Christopher, J. de Sèze, M. S. Freedman, et al.. (2016). Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II). Multiple Sclerosis Journal. 22(2). 327–328. 1 indexed citations
11.
12.
LaGanke, Christopher, et al.. (2016). Early Experience of 250 Multiple Sclerosis Patients Treated with Alemtuzumab in a United States MS Center (P3.086). Neurology. 86(16_supplement). 1 indexed citations
13.
LaGanke, Christopher, et al.. (2016). An Evaluation of the Longitudinal Stability of Anti-JC Virus (JCV) Antibody Levels in Patients with Multiple Sclerosis (MS) (P3.093). Neurology. 86(16_supplement). 1 indexed citations
14.
15.
LaGanke, Christopher, Regina Berkovich, Jeffrey Cohen, et al.. (2015). Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P3.261). Neurology. 84(14_supplement). 2 indexed citations
16.
LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations
17.
18.
LaGanke, Christopher, et al.. (2000). Cross-reactive idiotypy in cerebrospinal fluid immunoglobulins in multiple sclerosis. Annals of Neurology. 47(1). 87–92. 2 indexed citations
19.
Maier, Curtis C., et al.. (1998). A cross‐reactive anti‐myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis. Neurology. 50(2). 411–417. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yusuke Terada Breakdown of academic impact, for papers by Raffaele Murru Breakdown of academic impact, for papers by D. Teitelbaum Breakdown of academic impact, for papers by S. Galgani Breakdown of academic impact, for papers by René M. Gieß Breakdown of academic impact, for papers by Ciro Florio Breakdown of academic impact, for papers by Magdalena Lindén Breakdown of academic impact, for papers by Maria Roberta Bongioanni Breakdown of academic impact, for papers by Ayal Rozenberg Breakdown of academic impact, for papers by Laura Boos
Rankless by CCL
2026